Status:
COMPLETED
A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With Hypertension
Lead Sponsor:
Novartis
Conditions:
HYPERTENSION
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
A ONE YEAR SAFETY STUDY FOR PATIENTS WHO COMPLETE STUDY VAA489A2307.
Eligibility Criteria
Inclusion
- SUCCESSFUL COMPLETION OF VAA489A2307 CORE TRIAL
- VISIT 7 BLOOD PRESSURE MUST BE MSDBP ≤ 95 mmHg AND MSSBP ≤ 150 mmHg
Exclusion
- PATIENTS WHO EXPERIENCED ANY ADVERSE EVENTS CONSIDERED SERIOUS AND DRUG RELATED IN VAA489A2307 CORE
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2005
Estimated Enrollment :
403 Patients enrolled
Trial Details
Trial ID
NCT00170976
Start Date
April 1 2004
End Date
June 1 2005
Last Update
October 12 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Sites in germany
Multiple Locations, Germany
2
Novartis Pharmaceuticals
Basel, Switzerland